|
Chapter 1 Computational Chemistry and Molecular Modelling Basics |
|
|
1 | (38) |
|
|
|
|
|
|
1 | (1) |
|
1.2 Techniques in Biomolecular Simulations |
|
|
2 | (11) |
|
1.2.1 Molecular Mechanics and Force Fields |
|
|
2 | (2) |
|
1.2.2 Basic Simulation Techniques |
|
|
4 | (4) |
|
1.2.3 Basic Data Analysis |
|
|
8 | (3) |
|
|
11 | (1) |
|
|
12 | (1) |
|
1.3 Protein Structure Prediction |
|
|
13 | (7) |
|
1.3.1 Sequence Alignment and Secondary Structure Prediction |
|
|
13 | (2) |
|
1.3.2 Comparative Modelling Approaches |
|
|
15 | (3) |
|
1.3.3 Function Prediction |
|
|
18 | (1) |
|
1.3.4 Analysing the Quality of the Modelled Structure |
|
|
18 | (1) |
|
1.3.5 Software and Web Based Servers |
|
|
19 | (1) |
|
1.4 Computer-based Drug Design |
|
|
20 | (19) |
|
1.4.1 Pre-requisites for SBDD---Sampling Algorithms and Scoring Functions |
|
|
20 | (4) |
|
1.4.2 Structure Based Drug Design (SBDD) |
|
|
24 | (2) |
|
1.4.3 Ligand Based Drug Design (LBDD) |
|
|
26 | (1) |
|
|
26 | (1) |
|
1.4.5 Compound Optimisation |
|
|
27 | (2) |
|
1.4.6 Software and Web Based Servers |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
30 | (9) |
|
Chapter 2 Molecular Dynamics Computer Simulations of Biological Systems |
|
|
39 | (30) |
|
|
|
|
|
|
39 | (1) |
|
2.2 The Basics of Molecular Dynamics |
|
|
40 | (6) |
|
2.2.1 Force Fields for Biomolecular Simulations |
|
|
41 | (3) |
|
2.2.2 Multiscale Modelling |
|
|
44 | (1) |
|
2.2.3 Advanced Force Fields |
|
|
45 | (1) |
|
2.3 Extracting the Information from MD |
|
|
46 | (8) |
|
2.3.1 Free Energy Difference Between Two States |
|
|
47 | (1) |
|
2.3.2 Enhanced Configurational Sampling |
|
|
47 | (2) |
|
2.3.3 Simulating Rare Events |
|
|
49 | (1) |
|
2.3.4 Computing Elastic Properties in Biomolecular Simulations |
|
|
50 | (4) |
|
2.4 MD Simulation vs. Experiment |
|
|
54 | (4) |
|
2.4.1 NMR and MD: Structure and Dynamics |
|
|
55 | (2) |
|
2.4.2 Structure of Biomolecules and Diffraction: Solving the Phase Problem with MD |
|
|
57 | (1) |
|
|
58 | (3) |
|
|
61 | (8) |
|
|
63 | (1) |
|
|
63 | (6) |
|
Chapter 3 Designing Chemical Tools with Computational Chemistry |
|
|
69 | (18) |
|
|
|
|
69 | (3) |
|
3.2 Structure Based Approaches for Chemical Biology |
|
|
72 | (2) |
|
3.3 Structural Dynamics as a Source of Novel Chemical Tools |
|
|
74 | (5) |
|
3.4 Combining Bioinformatics, Chemoinformatics and Structural Information to Explore Protein Functions |
|
|
79 | (2) |
|
3.5 Deep Networks and Big Data in the Discovery of New Drugs and Chemical Tools |
|
|
81 | (2) |
|
3.6 Conclusions and Perspectives |
|
|
83 | (4) |
|
|
84 | (3) |
|
Chapter 4 Computational Design of Protein Function |
|
|
87 | (21) |
|
|
|
|
|
87 | (2) |
|
4.2 The `Inside-out' Design Protocol |
|
|
89 | (5) |
|
4.2.1 Description of the Method |
|
|
89 | (3) |
|
4.2.2 Enzymes Designed Though the `Inside-out' Approach: Kemp Eliminases |
|
|
92 | (2) |
|
4.3 QM/MM Approaches to Enzyme Design |
|
|
94 | (7) |
|
4.3.1 Description of the Methods |
|
|
94 | (2) |
|
4.3.2 Engineered Butyrylcholinesterase for Cocaine Detoxification |
|
|
96 | (3) |
|
4.3.3 Electron Transfer Reactions Catalysed by Metalloproteins |
|
|
99 | (2) |
|
|
101 | (7) |
|
|
102 | (1) |
|
|
102 | (6) |
|
Chapter 5 Computational Enzymology: Modelling Biological Catalysts |
|
|
108 | (37) |
|
|
|
|
|
108 | (1) |
|
|
109 | (5) |
|
5.2.1 The Transition State and the Energy Barrier |
|
|
109 | (1) |
|
5.2.2 Quantum Mechanics Molecular Mechanics (QM/MM) Methods |
|
|
110 | (4) |
|
5.3 Building the Model(s) of the Enzyme-Substrate Complex(es) |
|
|
114 | (1) |
|
5.3.1 Starting Structure and System Setup |
|
|
114 | (1) |
|
5.3.2 Molecular Dynamics Simulations |
|
|
114 | (1) |
|
5.4 Potential Energy Methods |
|
|
115 | (7) |
|
5.4.1 Reaction Path Calculation |
|
|
115 | (2) |
|
5.4.2 Transition State Localisation |
|
|
117 | (1) |
|
|
118 | (4) |
|
5.5 Free Energy Simulations |
|
|
122 | (14) |
|
5.5.1 Umbrella Sampling Method |
|
|
123 | (4) |
|
5.5.2 Free Energy Perturbation Theory |
|
|
127 | (5) |
|
5.5.3 String Method: Minimum Free Energy Paths |
|
|
132 | (4) |
|
5.6 Calculation of the Reaction Rate Constant |
|
|
136 | (3) |
|
5.6.1 Ensemble-averaged Variational Transition State Theory with Multi-dimensional Tunnelling (EA-VTST/MT) |
|
|
136 | (3) |
|
5.7 Further Considerations about the Relationship between the Activation Free Energy and the Extension of the Sampling of the Configurational Space |
|
|
139 | (6) |
|
|
141 | (4) |
|
Chapter 6 Computational Chemistry Tools in Glycobiology: Modelling of Carbohydrate-Protein Interactions |
|
|
145 | (20) |
|
|
|
|
|
Sonsoles Martin-Santamaria |
|
|
6.1 What are the Carbohydrates? |
|
|
145 | (2) |
|
6.2 From Mono to Polysaccharides: An Overview of the Increasing Complexity |
|
|
147 | (4) |
|
|
147 | (1) |
|
6.2.2 Disaccharides: The Glycosidic Linkage and the Exo-anomeric Effect |
|
|
148 | (1) |
|
6.2.3 Studying the Conformations Around the Glycosidic Linkage |
|
|
149 | (1) |
|
|
149 | (1) |
|
|
150 | (1) |
|
|
150 | (1) |
|
6.3 Computational Methodologies for the Study of Carbohydrates |
|
|
151 | (2) |
|
6.4 Force Fields for Carbohydrates |
|
|
153 | (2) |
|
6.5 Modelling Carbohydrate-Protein Interactions |
|
|
155 | (4) |
|
|
159 | (6) |
|
|
159 | (1) |
|
|
159 | (6) |
|
Chapter 7 Molecular Modelling of Nucleic Acids |
|
|
165 | (33) |
|
|
|
|
|
|
|
|
165 | (1) |
|
|
166 | (1) |
|
7.2.1 Basic Methodological Description |
|
|
166 | (1) |
|
|
167 | (1) |
|
|
167 | (3) |
|
7.3.1 Basic Methodological Description |
|
|
167 | (1) |
|
|
168 | (2) |
|
7.4 Atomistic Force-field Simulations |
|
|
170 | (7) |
|
7.4.1 Basic Methodological Description |
|
|
170 | (2) |
|
7.4.2 Force-field Refinements |
|
|
172 | (3) |
|
7.4.3 Recent Examples of Force-field Studies of Nucleic Acids |
|
|
175 | (2) |
|
7.5 The Coarse-grain Approach |
|
|
177 | (7) |
|
7.5.1 Basic Methodological Description |
|
|
178 | (4) |
|
7.5.2 Coarse-grained Methods for Predicting RNA Structures |
|
|
182 | (2) |
|
|
184 | (4) |
|
7.6.1 Basic Methodological Description |
|
|
185 | (1) |
|
7.6.2 Nucleosome Fibre Simulations |
|
|
186 | (1) |
|
7.6.3 Chromosome Simulations |
|
|
187 | (1) |
|
|
188 | (10) |
|
|
188 | (1) |
|
|
189 | (9) |
|
Chapter 8 Uncovering GPCR and G Protein Function by Protein Structure Network Analysis |
|
|
198 | (23) |
|
|
|
|
198 | (3) |
|
|
201 | (4) |
|
|
201 | (1) |
|
|
201 | (4) |
|
8.3 Results and Discussion |
|
|
205 | (11) |
|
8.3.1 Modelling Allosteric Communication in GPCRs |
|
|
205 | (8) |
|
8.3.2 Modelling Allosteric Communication in G Proteins |
|
|
213 | (3) |
|
|
216 | (5) |
|
|
216 | (1) |
|
|
217 | (4) |
|
Chapter 9 Current Challenges in the Computational Modelling of Molecular Recognition Processes |
|
|
221 | (26) |
|
|
|
|
|
|
Sonsoles Martin-Santamaria |
|
|
9.1 Modelling the Dynamics of the Proteins |
|
|
221 | (3) |
|
9.2 Three-dimensional Structure Prediction and Homology Modelling |
|
|
224 | (1) |
|
9.3 Modelling of Protein-Protein Interactions |
|
|
225 | (1) |
|
9.4 Prediction of Protein-Protein Interactions: Docking |
|
|
226 | (3) |
|
9.5 Computational Studies of Complex Protein Systems |
|
|
229 | (3) |
|
9.6 Computational Modelling of Nanostructures |
|
|
232 | (5) |
|
9.6.1 Modelling of Gold Nanoparticles |
|
|
233 | (1) |
|
9.6.2 Modelling of Nanowires |
|
|
234 | (1) |
|
9.6.3 Modelling of Nanotubes |
|
|
235 | (1) |
|
9.6.4 Modelling of Nanomachines |
|
|
236 | (1) |
|
9.7 Models of Signalling Networks |
|
|
237 | (10) |
|
|
240 | (1) |
|
|
240 | (7) |
|
Chapter 10 Novel Insights into Membrane Transport from Computational Methodologies |
|
|
247 | (34) |
|
|
|
|
247 | (1) |
|
10.2 Computational Methods |
|
|
248 | (4) |
|
10.3 Unassisted Diffusion Across Lipid Bilayers |
|
|
252 | (3) |
|
10.4 Passive Transport by Ion Channels |
|
|
255 | (4) |
|
10.5 Facilitated Diffusion by Transporters |
|
|
259 | (5) |
|
10.6 Signalling via Receptors |
|
|
264 | (4) |
|
|
268 | (13) |
|
|
268 | (1) |
|
|
269 | (12) |
|
Chapter 11 Application of Molecular Modelling to Speed-up the Lead Discovery Process |
|
|
281 | (36) |
|
|
|
|
|
281 | (5) |
|
11.1.1 The `Pharmaceutical Crisis' |
|
|
281 | (1) |
|
11.1.2 The Drug Discovery Process |
|
|
282 | (2) |
|
11.1.3 The Contribution of Molecular Modelling to Improve Drug Discovery |
|
|
284 | (1) |
|
11.1.4 Quantum and Molecular Mechanics in Drug Design |
|
|
285 | (1) |
|
11.1.5 An Introduction to Structure- and Ligand-based Molecular Modelling |
|
|
285 | (1) |
|
11.2 Structure-based Molecular Modelling |
|
|
286 | (10) |
|
11.2.1 Sources of 3D Structures |
|
|
286 | (3) |
|
|
289 | (2) |
|
11.2.3 De Novo Drug Design |
|
|
291 | (2) |
|
11.2.4 Introducing Dynamics |
|
|
293 | (3) |
|
11.3 Ligand-based Molecular Modelling |
|
|
296 | (9) |
|
11.3.1 Similarity Searching: Same Shape, Same Activity |
|
|
297 | (2) |
|
11.3.2 Pharmacophore Modelling |
|
|
299 | (1) |
|
|
300 | (4) |
|
11.3.4 Use of In Silico Ligand-based Approaches: A Practical Case Study on Antitubercular Agents |
|
|
304 | (1) |
|
|
305 | (12) |
|
|
306 | (1) |
|
|
307 | (1) |
|
|
307 | (10) |
|
Chapter 12 Molecular Modelling and Simulations Applied to Challenging Drug Discovery Targets |
|
|
317 | (32) |
|
|
|
|
|
317 | (2) |
|
12.2 Deciphering Metalloenzyme Catalysis via Computations |
|
|
319 | (4) |
|
|
319 | (2) |
|
|
321 | (2) |
|
12.3 Simulating Membrane Proteins |
|
|
323 | (8) |
|
12.3.1 Membrane Enzymes: The Case of FAAH |
|
|
323 | (1) |
|
12.3.2 Ion Channels: The Case of the Kv11.1 Channel |
|
|
324 | (4) |
|
12.3.3 GPCR: The Case of the Human Adenosine Receptor A2A Embedded in Neuronal-like Membrane |
|
|
328 | (3) |
|
12.4 Tackling Target Flexibility Through Simulations |
|
|
331 | (7) |
|
12.4.1 Lactate Dehydrogenase |
|
|
331 | (2) |
|
12.4.2 Intrinsically Disordered Proteins |
|
|
333 | (2) |
|
12.4.3 Targeting RNA in Trinucleotide Repeats Diseases |
|
|
335 | (3) |
|
|
338 | (11) |
|
|
338 | (11) |
|
Chapter 13 The Polypharmacology Gap Between Chemical Biology and Drug Discovery |
|
|
349 | (22) |
|
|
|
13.1 Introduction: Chemical Biology and the Limits of Reductionism |
|
|
349 | (4) |
|
13.1.1 Polypharmacology in Drug Discovery |
|
|
349 | (2) |
|
13.1.2 Selectivity in Chemical Biology |
|
|
351 | (2) |
|
13.2 Systems Pharmacology: Databases and Methods |
|
|
353 | (2) |
|
13.2.1 Databases of Chemical, Biological and Pharmacological Data |
|
|
353 | (1) |
|
13.2.2 Computational Methods to Predict Polypharmacology |
|
|
354 | (1) |
|
13.3 Case Study 1: The Impact of Chemical Probe Polypharmacology on PARP Drug Discovery |
|
|
355 | (8) |
|
13.3.1 The History of PARP Biology: From Probes to Drugs |
|
|
355 | (2) |
|
13.3.2 PJ34: A PARP Chemical Tool Binding to PIM Kinases |
|
|
357 | (3) |
|
13.3.3 Differential Off-target Kinase Pharmacology Between Clinical PARP Inhibitors |
|
|
360 | (3) |
|
13.4 Case Study 2: Distant Off-target Pharmacology among MLP Chemical Probes |
|
|
363 | (2) |
|
13.5 Conclusions and Outlook |
|
|
365 | (6) |
|
|
366 | (1) |
|
|
366 | (5) |
Subject Index |
|
371 | |